# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Benchmark analyst Robert Wasserman upgrades BioLife Solns (NASDAQ:BLFS) from Hold to Buy and announces $25 price target.
2024 Revenue GuidanceBioLife Solutions is affirming its 2024 revenue guidance of $95.5 million to $100.0 million. This is based...
BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.28)...
Jefferies analyst Matthew Stanton initiates coverage on BioLife Solns (NASDAQ:BLFS) with a Buy rating and announces Price Ta...
BioLife Solns (NASDAQ:BLFS) reported quarterly losses of $(0.210) per share which beat the analyst consensus estimate of $(0.34...